Refine
Year of publication
Document Type
- Article (70)
- Conference Proceeding (1)
Has Fulltext
- yes (71)
Is part of the Bibliography
- no (71)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- metastatic (3)
- Alpelisib (2)
- Atezolizumab (2)
- CRM (2)
- Diagnostik (2)
- Früherkennung (2)
- Katherine (2)
- Lokalrezidiv (2)
- Nachsorge (2)
- Nuclear reactions (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Shell model (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- chemotherapy (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- stroke (2)
- studies (2)
- supportive therapy (2)
- treatment/therapy (2)
- ACURATE neo (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Acute coronary syndrome (1)
- Advanced breast cancer (1)
- Antihormone therapy (1)
- Artificial Intelligence (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atrial fibrillation (1)
- Atxn2 (1)
- Beam loss (1)
- Biodiversity Data (1)
- Biological markers (1)
- Biomonitoring (1)
- Botanical Collections (1)
- Calcium (1)
- Cardiac troponin (1)
- Cell cycle (1)
- Cell membranes (1)
- Cerebellar ataxia (1)
- Cerebellum (1)
- Charge-transfer collisions (1)
- Chemokine CCL2 (1)
- Chemokines (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Colon capsule endoscopy (1)
- Communication (1)
- Complementation rate (1)
- Conservation (1)
- Diagnosis (1)
- Digitization (1)
- Direct reactions (1)
- Electronic transitions (1)
- Endocrinology (1)
- Frontotemporal dementia (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Halogenation (1)
- Heavy ion storage ring (1)
- Herbaria (1)
- Heregulin (1)
- High-energy neutron detection (1)
- Homeostasis (1)
- Incomplete colonoscopy (1)
- Interleukin-17A (1)
- Inverse kinematics (1)
- Iodine (1)
- Itpr1 (1)
- Kidney diseases (1)
- Library screening (1)
- Lipid trafficking (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Luciferase (1)
- MM-121 (1)
- Metastatic (1)
- Motor neuron disease (1)
- Moviprep (1)
- Multi-neutron detection (1)
- Myocardial infarction (1)
- Nuclear astrophysics (1)
- Nuclear physics of explosive environments (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- Orbital electron capture (1)
- Patient safety (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- PillCamColon2 (1)
- Plastic scintillator array (1)
- Polycyclic aromatic hydrocarbons (1)
- Polyps (1)
- Prostatic neoplasms (1)
- Quality management (1)
- Quasi-free scattering (1)
- RNA processing machinery (1)
- Radiative capture (1)
- Reactions with relativistic radioactive beams (1)
- Research Infrastructure (1)
- Retinal diseases (1)
- Risk reduction (1)
- Rora (1)
- SNP (1)
- Semantics (1)
- Seribantumab (1)
- Signaling (1)
- Single particle decay spectroscopy (1)
- Small molecules (1)
- Spectroscopic factors (1)
- Spectroscopic factors & electromagnetic moments (1)
- Synthetic methods (1)
- T-DM1 (1)
- TAVR (1)
- TIA-1 (1)
- Taxonomy (1)
- Transcriptome (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- Urology (1)
- Vesicles (1)
- advanced breast cancer (1)
- antihormone therapy (1)
- aortic stenosis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- data quality (1)
- dynamic stimuli (1)
- electroencephalography (EEG) (1)
- embodiment (1)
- emergency care (1)
- facial EMG (1)
- facial emotion recognition (1)
- facial expressions of emotion (1)
- facial muscle activity (1)
- hypertension and anti-hypertensive treatment (1)
- imitation (1)
- lapatinib (1)
- leukopenia (1)
- metastasis (1)
- multicenter study (1)
- neutropenia (1)
- pertuzumab (1)
- polymorphism (1)
- psoriasis (1)
- simulation (1)
- simulation training (1)
- telmisartan (1)
- thrombolysis (1)
- thrombolysis (tPA) (1)
- training (1)
- transcatheter aortic valve replacement (1)
- transfemoral (1)
- trastuzumab (1)
- vascular dysfunction and inflammation (1)
- videos (1)
- x-ray techniques (1)
Institute
- Medizin (34)
- Physik (25)
- ELEMENTS (9)
- Biochemie und Chemie (6)
- Geowissenschaften (3)
- Biowissenschaften (1)
- Pharmazie (1)
- Senckenbergische Naturforschende Gesellschaft (1)
Purpose: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa.
Materials and methods: Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested.
Results: The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading.
Conclusion: Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.